Chime Biologics and Panolos Bioscience have entered into a global strategic collaboration agreement on a novel multi-specific protein drug. Chime Biologics will provide development and manufacturing services to Panolos Bioscience for PB203, a next-generation immuno-oncology drug.

Chime Biologics和Panolos Bioscience已就新型多特异性蛋白质药物达成全球战略合作协议。Chime Biologics将为Panolos Bioscience提供下一代免疫肿瘤药物PB203的开发和制造服务。

WUHAN, China and HWASEONG-SI, South Korea, Sept. 22, 2023 /PRNewswire/ -- Chime Biologics, a leading CDMO that enables biologic therapeutics development announced a strategic cooperation agreement with Panolos Bioscience, a South Korean biotech company to accelerate multi-specific protein development, at a signing ceremony held in Optics Valley Wuhan, Hubei Province on the 19th of September.

2023年9月22日，中国武汉和韩国HWASEONG-SI/PRNewswire/-Chime Biologics是一家领先的CDMO，能够促进生物治疗药物的开发，宣布与韩国生物技术公司Panolos Bioscience签订战略合作协议，加速多特异性蛋白质开发，于9月19日在湖北省武汉市光学谷举行的签署式上。

Dr. HyeSeong Lim, Founder and CEO of Panolos Bioscience, and Mr. YoungHoon Cho, Chief Business Officer of Panolos Bioscience, as well as Chime Biologics' team attended the signing ceremony..

Panolos Bioscience的创始人兼首席执行官HyeSeong Lim博士，Panolos Bioscience首席商务官Cho YoungHoon先生以及Chime Biologics团队参加了签署仪式。。

Panolos Bioscience, located in the suburb of Seoul, Korea, is a biopharmaceutical company focused on the development of multi-specific therapeutics to treat cancer, auto-immune diseases and rare diseases. Panolos Bioscience has entered into a collaboration with Chime Biologics for a novel multi-specific protein drug, PB203, for solid tumors (PDAC/ICC), which is in the preclinical stage with plans to conduct clinical trial Phase I in the US.

Panolos Bioscience位于韩国首尔郊区，是一家生物制药公司，致力于开发治疗癌症，自身免疫疾病和罕见疾病的多特异性治疗药物。Panolos Bioscience已与Chime Biologics合作，开发了一种用于实体瘤的新型多特异性蛋白药物PB203（PDAC/ICC），该药物处于临床前阶段，计划在美国进行临床试验I期。

Chime Biologics will provide an one-stop biologic CMC solution for the development and manufacturing of PB203 from cell line development, process development, and GMP manufacturing service. And it will be based on the unique Chime's CHOrus platform, which has a highly productive, rapid, and stable cell line development capability to select the optimal stable expression clones based on expression titer and quality..

Chime Biologics将为细胞系开发，工艺开发和GMP制造服务开发和制造PB203提供一站式生物CMC解决方案。它将基于Chime独特的CHOrus平台，该平台具有高产，快速，稳定的细胞系开发能力，可根据表达滴度和质量选择最佳稳定表达克隆。。

The leaders from the Consulate General of the Republic of Korea, Foreign Affairs Office of Wuhan Municipal People's Government, Wuhan East Lake High-tech Development Zone, and Wuhan National Bio-Industry Base Construction Management Office witnessed the signing ceremony, and this agreement underlines the strong collaboration between China and Korea..

大韩民国总顾问，武汉市人民政府外交厅，武汉东湖高科技开发区和武汉国家生物产业基地建设管理办公室的领导人见证了签署会议，本协议强调了强有力的中韩合作。。

Dr. HyeSeong Lim, Founder and CEO of Panolos Bioscience, said, 'We are pleased to be a global strategic partner with Chime Biologics, and the co-development of PB203 is an important start in establishing our long-term strategic cooperation in Wuhan, China, covering commercial manufacturing. This is the first step in our shared mission to the commercialization of innovative medicines, starting from China and spreading to the world.

Panolos Bioscience的创始人兼首席执行官HyeSeong Lim博士说：“我们很高兴成为Chime Biologics的全球战略合作伙伴，PB203的共同开发是在武汉建立长期战略合作的重要开端，中国，涵盖商业制造业。这是我们从中国开始向世界传播创新药物商业化共同使命的第一步。

By partnering with global CDMO Chime Biologics, we will do our best to bring hope and a new life to our patients.'.

通过与全球CDMO Chime Biologics合作，我们将尽最大努力为患者带来希望和新生活。

Dr. Jimmy Wei, President of Chime Biologics, said, ' We are very excited to work with Panolos Bioscience to drive the project to Wuhan, China, taking unique advantage of Chime's CHOrus cell line development platform that enables the US clinical trials and global sampling. This is not only a recognition of Chime Biologics' new business model and international quality system, but also an important development journey for Chime Biologics to go globally.

Chime Biologics总裁Jimmy Wei博士说：“我们非常高兴与Panolos Bioscience合作，推动该项目进入中国武汉，利用Chime的CHOrus细胞系开发平台，实现美国临床试验和全球采样。这不仅是对Chime生物制品新业务模式和国际质量体系的认可，也是Chime生物制品走向全球的重要发展历程。

We believe that Chime Biologics' high-quality platform and rich experience will facilitate the global R&D, clinical trials and future commercial manufacturing of multi-specific therapeutic proteins.'.

我们相信Chime Biologics的高质量平台和丰富的经验将促进全球研发，临床试验和未来多特异性治疗蛋白的商业制造。

About PB203PB203, a multi-specific protein targeting VEGF, PIGF, and PD-L1, is currently in pre-clinical development as a potential remedy for solid tumors, notably pancreatic cancer. Its promising efficacy, published in Nature Communication in 2022, was further accentuated during an oral presentation at this year's Immuno-Oncology Summit in the US.

关于PB203PB203，一种靶向VEGF，PIGF和PD-L1的多特异性蛋白，目前正在临床前开发中，作为实体瘤，特别是胰腺癌的潜在治疗方法。在今年美国免疫肿瘤学峰会的口头报告中，其在2022年发表在Nature Communication上的有希望的功效得到了进一步强调。

This notable discourse emphasized its clear therapeutic mechanism and potential impact on pancreatic cancer treatment..

这一着名的讨论强调了其明确的治疗机制和对胰腺癌治疗的潜在影响。。

About CHOrusChime Biologics has a highly productive, rapid, and stable cell line development platform to select the optimal stable expression clones based on expression titer and quality. The cell line development is based on our proprietary and highly expressed CHO system. Chime's CHO-K1-derived cell lines have a clear history of use and are tested and qualified.

关于CHOrusChime Biologics拥有高效，快速，稳定的细胞系开发平台，可根据表达滴度和质量选择最佳稳定表达克隆。细胞系开发基于我们专有且高度表达的CHO系统。Chime的CHO-K1衍生细胞系具有明确的使用历史，并经过测试和鉴定。

We use advanced single-cell printers and high-resolution imaging systems to ensure cell line monoclonality and shorten the screening time. Cell line generation and monoclonality are fully documented and traceable according to regulatory requirements. Expression titer can exceed 10 g/L..

我们使用先进的单细胞打印机和高分辨率成像系统来确保细胞系单克隆性并缩短筛选时间。根据监管要求，细胞系的产生和单克隆性得到充分记录和可追溯。表达滴度可超过10 g/L。。

About Panolos BiosciencePanolos Bioscience is a clinically staged frontrunner in structure-based protein design and development. Panolos focused on the development of therapeutics for cancer, anti-immune and rare diseases, with a proprietary αART technology that enhances the efficacy of mono-specific or multi-specific antibody therapies through the use of the VEGF receptor backbone.

关于Panolos BiosciencePanolos Bioscience是基于结构的蛋白质设计和开发的临床领先者。Panolos专注于开发癌症，抗免疫和罕见疾病的治疗药物，采用专有的αART技术，通过使用VEGF受体骨架增强单特异性或多特异性抗体疗法的功效。

For more information, please visit www.panolos.com..

欲了解更多信息，请访问www.panolos.com。。

About Chime BiologicsChime Biologics is a leading CDMO that has introduced the first modular biopharmaceutical plant KUBio in the world to empower its partners' success in biologics in the whole process from cell line development to commercial manufacturing. Relying on cell line development and advanced technology development from our Shanghai Innovation Center and proven success in IND-enabling through BLA filing at its Wuhan plant, Chime Biologics is providing a one-stop CMC solution for biopharmaceutical customers around the world.

关于Chime BiologicsChime Biologics是一家领先的CDMO，它引入了世界上第一家模块化生物制药厂KUBio，使其合作伙伴在从细胞系开发到商业制造的整个过程中在生物制剂方面取得成功。Chime Biologics依靠上海创新中心的细胞系开发和先进技术开发，通过在武汉工厂进行BLA申请，证明IND成功实现，为全球生物制药客户提供一站式CMC解决方案。

We share a common goal to make cutting-edge biomedicines affordable and accessible to all patients globally, fulfilling its commitment to human health. For more information, please visit www.chimebiologics.com..

我们共同的目标是使全球所有患者都能负担得起和使用尖端生物医学，履行其对人类健康的承诺。欲了解更多信息，请访问www.chimebiologics.com。。

SOURCE Chime Biologics

来源Chime Biologics